HomeCompareMYOV vs MO

MYOV vs MO: Dividend Comparison 2026

MYOV yields 7.41% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $47.4K in total portfolio value· pulled ahead in Year 7
10 years
MYOV
MYOV
● Live price
7.41%
Share price
$26.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.7K
Annual income
$1,186.18
Full MYOV calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — MYOV vs MO

📍 MO pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYOVMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYOV + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYOV pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYOV
Annual income on $10K today (after 15% tax)
$630.10/yr
After 10yr DRIP, annual income (after tax)
$1,008.25/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $24,627.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYOV + MO for your $10,000?

MYOV: 50%MO: 50%
100% MO50/50100% MYOV
Portfolio after 10yr
$56.4K
Annual income
$15,672.67/yr
Blended yield
27.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

MYOV
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-3.0
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYOV buys
0
MO buys
0
No recent congressional trades found for MYOV or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYOVMO
Forward yield7.41%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$32.7K$80.1K
Annual income after 10y$1,186.18$30,159.17
Total dividends collected$9.7K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: MYOV vs MO ($10,000, DRIP)

YearMYOV PortfolioMYOV Income/yrMO PortfolioMO Income/yrGap
1$11,441$741.29$10,570$780.30+$871.00MYOV
2$13,035$792.65$11,381$1,032.90+$1.7KMYOV
3$14,791$843.97$12,535$1,392.73+$2.3KMYOV
4$16,722$895.04$14,193$1,920.91+$2.5KMYOV
5$18,838$945.65$16,618$2,723.68+$2.2KMYOV
6$21,152$995.63$20,263$3,993.80+$889.00MYOV
7← crossover$23,678$1,044.81$25,936$6,098.36$2.3KMO
8$26,428$1,093.05$35,166$9,775.01$8.7KMO
9$29,418$1,140.20$51,026$16,597.78$21.6KMO
10$32,664$1,186.18$80,113$30,159.17$47.4KMO

MYOV vs MO: Complete Analysis 2026

MYOVStock

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Full MYOV Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this MYOV vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYOV vs SCHDMYOV vs JEPIMYOV vs OMYOV vs KOMYOV vs MAINMYOV vs PMMYOV vs BTIMYOV vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.